These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33917026)

  • 61. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P; Chao BH; Litz J; Krystal GW
    Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
    Glytsou C; Chen X; Zacharioudakis E; Al-Santli W; Zhou H; Nadorp B; Lee S; Lasry A; Sun Z; Papaioannou D; Cammer M; Wang K; Zal T; Zal MA; Carter BZ; Ishizawa J; Tibes R; Tsirigos A; Andreeff M; Gavathiotis E; Aifantis I
    Cancer Discov; 2023 Jul; 13(7):1656-1677. PubMed ID: 37088914
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The novel small molecular BH3 mimetics SM3 and its regulation of cell apoptosis and autophagy.
    Wang Y; Fan S; Li X; Xiaokaiti Y; Pan Y; Tie L; Li X
    Biochem Biophys Res Commun; 2019 Sep; 517(1):15-22. PubMed ID: 31303271
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells.
    Reinhart R; Rohner L; Wicki S; Fux M; Kaufmann T
    Cell Death Differ; 2018 Jan; 25(1):204-216. PubMed ID: 28960207
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells.
    Ye L; Yuan G; Xu F; Sun Y; Chen Z; Chen M; Li T; Sun P; Li S; Sun J
    Tumour Biol; 2015 May; 36(5):3447-55. PubMed ID: 25542230
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
    Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
    Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise.
    Sarosiek KA; Letai A
    FEBS J; 2016 Oct; 283(19):3523-3533. PubMed ID: 26996748
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
    Abed MN; Abdullah MI; Richardson A
    J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Knockdown of BAG3 sensitizes bladder cancer cells to treatment with the BH3 mimetic ABT-737.
    Mani J; Antonietti P; Rakel S; Blaheta R; Bartsch G; Haferkamp A; Kögel D
    World J Urol; 2016 Feb; 34(2):197-205. PubMed ID: 26100943
    [TBL] [Abstract][Full Text] [Related]  

  • 70. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
    Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
    Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
    Paoluzzi L; Gonen M; Gardner JR; Mastrella J; Yang D; Holmlund J; Sorensen M; Leopold L; Manova K; Marcucci G; Heaney ML; O'Connor OA
    Blood; 2008 Jun; 111(11):5350-8. PubMed ID: 18292288
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
    Li D; Lopez A; Shrivastava N; Chan W; Thomas C; Burk R; Segall J; Augustine S; Rosenblatt G; Mehta V; Schiff BA; Smith RV; Prystowsky MB; Schlecht NF; Guha C; Gavathiotis E; Ow TJ
    Oral Oncol; 2024 Dec; 159():107069. PubMed ID: 39423550
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lauric acid can improve the sensitization of Cetuximab in KRAS/BRAF mutated colorectal cancer cells by retrievable microRNA-378 expression.
    Weng WH; Leung WH; Pang YJ; Hsu HH
    Oncol Rep; 2016 Jan; 35(1):107-16. PubMed ID: 26496897
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Mitochondrial Profiling of Acute Myeloid Leukemia in the Assessment of Response to Apoptosis Modulating Drugs.
    Ishizawa J; Kojima K; McQueen T; Ruvolo V; Chachad D; Nogueras-Gonzalez GM; Huang X; Pierceall WE; Dettman EJ; Cardone MH; Shacham S; Konopleva M; Andreeff M
    PLoS One; 2015; 10(9):e0138377. PubMed ID: 26375587
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.
    Nakajima W; Sharma K; Hicks MA; Le N; Brown R; Krystal GW; Harada H
    Cancer Biol Ther; 2016; 17(1):27-35. PubMed ID: 26575826
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Bak and Bcl-xL Participate in Regulating Sensitivity of Solid Tumor Derived Cell Lines to Mcl-1 Inhibitors.
    Senichkin VV; Pervushin NV; Zamaraev AV; Sazonova EV; Zuev AP; Streletskaia AY; Prikazchikova TA; Zatsepin TS; Kovaleva OV; Tchevkina EM; Zhivotovsky B; Kopeina GS
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008345
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein.
    Abid M; Sonawane YA; Contreras JI; Rana S; Natarajan A
    Curr Med Chem; 2017; 24(40):4488-4514. PubMed ID: 28901269
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL.
    Le Pen J; Maillet L; Sarosiek K; Vuillier C; Gautier F; Montessuit S; Martinou JC; Letaï A; Braun F; Juin PP
    Cell Death Dis; 2016 Feb; 7(2):e2083. PubMed ID: 26844698
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity.
    Soderquist RS; Crawford L; Liu E; Lu M; Agarwal A; Anderson GR; Lin KH; Winter PS; Cakir M; Wood KC
    Nat Commun; 2018 Aug; 9(1):3513. PubMed ID: 30158527
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells.
    Simonin K; Brotin E; Dufort S; Dutoit S; Goux D; N'diaye M; Denoyelle C; Gauduchon P; Poulain L
    Mol Cancer Ther; 2009 Nov; 8(11):3162-70. PubMed ID: 19887550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.